Last updated: February 13, 2026
Overview
NDC 49702-0212 corresponds to Polatuzumab Vedotin-piiq (Polivy), a monoclonal antibody-drug conjugate approved for certain types of B-cell non-Hodgkin lymphoma. Since its FDA approval in June 2019, it has captured a niche market within hematologic oncology.
Market Landscape
Market Penetration and Revenue Projections
| Year |
Estimated Patients Treated |
Estimated Revenue (USD) |
Assumptions |
| 2023 |
1,200 |
60 million |
6% penetration among R/R DLBCL patients |
| 2024 |
2,400 |
120 million |
12% penetration, growth in awareness and approvals |
| 2025 |
3,600 |
180 million |
Market expansion and increased clinician familiarity |
| 2026 |
4,500 |
225 million |
Continued growth, entry into second-line settings |
Price Trajectory
- Current Year (2023): WAC around $17,000 per vial; per treatment cycle estimated at $50,000-$70,000.
- Next 2-3 Years: Slight price renegotiations expected based on payer negotiations; potential volume discounts may yield net revenue declines.
- Long Term (2025-2027): Price stabilization; possible slight reduction due to biosimilar entry if applicable.
Pricing Trends & Influencing Factors
- Market Competition: Entry of new therapies could pressure pricing.
- Reimbursement Policies: Value-based arrangements could lower net prices over time.
- Manufacturing Costs: Advances in production may reduce costs, enabling pricing flexibility.
Regulatory and Reimbursement Outlook
- Coverage decisions by Medicare/Medicaid significantly influence physician prescribing patterns.
- Gains in formulary inclusion can accelerate market penetration.
Risk Factors
- Slow adoption due to clinician familiarity with existing regimens.
- New competitors or biosimilar entries could compress prices.
- Potential updates to treatment guidelines might restrict off-label use or reposition Polatuzumab.
Summary
Polatuzumab Vedotin-piiq's market remains niche but growing, with projected revenues reaching approximately $180 million in 2025 and potentially higher as indications expand. Pricing remains influenced by competition, reimbursement policies, and clinical uptake. Prices are expected to decrease marginally over time due to competitive pressures and volume increases.
Key Takeaways
- NDC 49702-0212’s market is centered on R/R DLBCL, with limited but expanding indications.
- Initial pricing is around $17,000 per vial (~$50,000-$70,000 per treatment cycle).
- Revenue projections suggest growth from $60 million in 2023 to over $180 million by 2025.
- Market entry barriers include clinician familiarity and reimbursement hurdles.
- Price erosion is likely in future years due to biosimilars and payer negotiations.
FAQs
1. What factors most affect the pricing of Polatuzumab Vedotin?
Reimbursement negotiations, market competition, manufacturing costs, and regulatory updates influence price setting.
2. How does the market size for this drug compare to similar therapies?
It is smaller; key competitors like Brentuximab Vedotin serve larger markets but have different indications.
3. Are biosimilars expected for Polatuzumab Vedotin?
Currently, no biosimilars are on the market; approval or entry could impact pricing and market share.
4. What is the outlook for expanding indications?
Potential expansion into earlier lines of therapy or other B-cell malignancies could increase market size.
5. How do reimbursement policies impact revenue?
Coverage decisions and formulary inclusion determine access and, consequently, revenue potential.
Sources
- FDA Approval and Label Data [1]
- industry reports on hematologic-oncology drug markets [2]
- Pricing data from IQVIA and First Databank [3]
- Market size estimates from CDC and NCCN guidelines [4]
- Competitive analysis from BioCentury [5]
[1] FDA, "Polatuzumab Vedotin-piiq (Polivy) Approval Letter," 2019.
[2] IBISWorld, "Hematologic Cancer Drugs Industry," 2022.
[3] IQVIA, "Drug Price and Utilization Data," 2023.
[4] CDC, "Cancer Statistics," 2022.
[5] BioCentury, "Market Trends in Hematologic Oncology," 2023.
